Bacteria will continue to develop resistance to antibiotics making treatments difficult or impossible. New antibiotic development is critical to address this, however any new drugs must be used infrequently which makes the venture unappealing to the industry. Fortunately, alternative methods exist to counteract this problem.Vaccines are one of the most promising endeavours because they cannot develop resistance. Designing clinical trials for new vaccines against the bacterial infections that pose the greatest risk to AMR will be essential for limiting their spread. Public-private partnerships are key players in antimicrobial R&D. IMI invests heavily in AMR to fund a wide range of studies into Gram-negative bacteria, monoclonal antibodies, rapid diagnostic tools, among others. A cooperative, networked community is essential to the success of these projects to best coordinate top experts.

To read the entire article, visit Innovative Medicine Initiatives website (Link)